Article

Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination With Nivolumab

2022-01-25

Abstract excerpt

Novel therapeutic approaches combining immune checkpoint inhibitors are needed to improve clinical outcomes for patients with cancer. Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint molecule that inhibits T-cell activity and antitumor immune responses, acting through an independent mechanism from that of programmed death-1 (PD-1) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4). Here, we descr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b09772ba-965a-56f9-abb7-0e46cce85d89
DOI: 10.1101/2022.01.24.477551

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination With NivolumabDOI 10.1101/2022.01.24.477551Read

LAG-3: from molecular functions to clinical applicationsSemantic proximity Read

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentialsSemantic proximity Read

Understanding LAG-3 SignalingSemantic proximity Read

LAG Time in the Era of Immunotherapy—New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene‐3Semantic proximity Read

Gene of the month: lymphocyte-activation gene 3 (LAG-3)Semantic proximity Read

Development and characterization of Novel Small Molecule Inhibitors Targeting LAG-3 ProteinSemantic proximity Read

LAG ‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeuticsSemantic proximity Read

Design and Validation of the First-in-Class PROTACs for Targeted Degradation of the Immune Checkpoint LAG-3Semantic proximity Read

Development of a LAG-3 Immunohistochemistry Assay for MelanomaSemantic proximity Read

Lymphocyte‐activation gene‐3, an important immune checkpoint in cancerSemantic proximity Read

Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.Semantic proximity Read

Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function.Semantic proximity Read